Brie, D and Sahebkar, A and Penson, P and Dinca, M and Ursoniu, S and Serban, M-C and Zanchetti, A and Howard, G and Ahmed, A and Aronow, WS and Muntner, P and Lip, GYH and Wong, ND and Rysz, J and Banach, M (2016) Effects of Pentoxifylline on Inflammatory Markers and Blood Pressure: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Journal of Hypertension, 34 (12). pp. 2318-2329. ISSN 1473-5598
JH Pentoxifylline For Symplectic Deposit.pdf - Accepted Version
Restricted to Repository staff only until 1 December 2017.
Introduction: Pentoxifylline is a xanthine derivative with potential cardiovascular benefits. Aim: To evaluate the impact of pentoxifylline on blood pressure and plasma tumor necrosis factor-α, C-reactive protein and interleukin-6 through a systematic review and meta-analysis of randomized controlled trials. Methods: The protocol was registered (PROSPERO: CRD42016035988). The search included PUBMED, ProQuest, Scopus, and EMBASE until September 1st 2015 to identify trials reporting blood pressure or inflammatory markers during pentoxifylline therapy. Quantitative data synthesis was performed using a random-effects model, with weighted mean difference and 95% confidence intervals as summary statistics. Results: 15 studies (16 treatment arms) were found to be eligible for inclusion. Meta-analysis did not suggest any effect of pentoxifylline on either systolic or diastolic blood pressure. Pentoxifylline treatment was associated with a significant reduction in plasma concentrations of tumor necrosis factor-α (weighted mean difference: -1.03 pg/mL, 95% confidence interval: -1.54, -0.51, p < 0.001, 11 treatment arms) and C-reactive protein (weighted mean difference: -1.39 mg/L, 95% confidence interval: -2.68, -0.10, p = 0.034, 5 treatment arms). No alteration in plasma interleukin-6 concentration was observed. The impact of pentoxifylline on plasma tumor necrosis factor-α levels was found to be positively associated with treatment duration (slope: 0.031; 95% confidence interval: 0.004, 0.057; p = 0.023) but independent of pentoxifylline dose (slope: -0.0003; 95% confidence interval: -0.002, 0.001; p = 0.687). Conclusions: Pentoxifylline did not alter blood pressure or plasma interleukin-6 concentration, but significantly reduced circulating tumor necrosis factor-α and C-reactive protein concentrations.
|Additional Information:||This is the accepted version of the following article: Journal of Hypertension, Brie etal. Effects of Pentoxifylline on Inflammatory Markers and Blood Pressure: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. 34(12), p. 2318-2329, which has been published in final form at http://dx.doi.org/10.1097/HJH.0000000000001086|
|Uncontrolled Keywords:||1103 Clinical Sciences, 1102 Cardiovascular Medicine And Haematology|
|Subjects:||R Medicine > RS Pharmacy and materia medica|
|Divisions:||Pharmacy & Biomolecular Sciences|
|Publisher:||Lippincott, Williams & Wilkins|
|Date Deposited:||26 Jul 2016 10:52|
|Last Modified:||05 Dec 2016 12:20|
|DOI or Identification number:||10.1097/HJH.0000000000001086|
Actions (login required)